Skip to content

Verily Watch Cardio (AF and ECG) Study

Verily Watch Cardio (AF and ECG) Study

Status
Withdrawn
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06041373
Enrollment
0
Registered
2023-09-18
Start date
2023-11-30
Completion date
2024-11-30
Last updated
2023-12-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Brief summary

This study is designed to evaluate the performance of the Verily Watch Cardio for recording electrocardiogram (ECG) and photoplethysmography (PPG) signals and detecting suspected atrial fibrillation (AF) episodes, in a free-living environment, in participants at risk for having an AF event.

Interventions

DEVICEVerily Watch Cardio

The Verily Watch Cardio is an investigational wrist-worn wearable device containing multiple sensors to measure physiological and environmental metrics, including electrodes that enable a single-lead electrocardiogram (ECG) measurement and a photoplethysmogram (PPG) sensor to monitor for irregular pulses.

DEVICEiRhythm Zio monitor

The iRhythm Zio monitor, the reference device, is an FDA-cleared single-patient use, continuously recording ECG monitor that can be worn for up to 14 days.

DEVICESchiller CARDIOVIT FT-1

The Schiller CARDIOVIT FT-1, the reference device, is an FDA-cleared portable 12-lead ECG machine capable of recording continuous standard 12-lead resting ECG for up to 4 minutes.

Sponsors

Verily Life Sciences LLC
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
22 Years to No maximum

Inclusion criteria

* At least 22 years old * Able to read and speak English * Participant understands the study requirements and is able and willing to sign written Informed Consent * At risk of having an AF event, as determined by having a diagnosis of paroxysmal AF (PAF) and meeting one or more of the following: 1. Scheduled or to be scheduled to undergo AF ablation 2. AF burden of ≥25% in the 3 months prior to consent date as confirmed via an implantable loop recorder (ILR), holter monitor, or adhesive monitoring patch 3. CHA2DS2VASc score ≥3 4. Left atrial diameter ≥4.4 cm as confirmed by transthoracic echo (TTE) within one year of consent * Without significant limitation in ability to participate in the study, in the opinion of the Investigator

Exclusion criteria

* Have a pacemaker or implantable cardioverter defibrillator (ICD) * Currently on class Ic or class III antiarrhythmic medication that has been successful in eliminating AF (no documented AF of more than 30 seconds since the initiation of the medication). Should be at least one week off medication. * Had successful AF ablation (no documented AF of more than 30 seconds post procedure) * Known severe allergy to nickel or metal jewelry * Known allergic reaction to polyester, nylon, spandex, adhesives or hydrogels; or with family history of adhesive skin allergies * Are diagnosed with persistent AF * Have an implantable neuro-stimulator * Currently wearing an ECG patch that prevents the use of the FDA-cleared wearable ECG patch, at the discretion of the Investigator. * Have discolored wrists (e.g., tattoos, ink), at the discretion of the Investigator.

Design outcomes

Primary

MeasureTime frameDescription
Sensitivity and Specificity of suspected AF episode detectionUp to 14 daysSensitivity and Specificity of suspected AF episode detection by the irregular pulse detection algorithm

Secondary

MeasureTime frameDescription
A sensitivity analysis estimating the range of sensitivities and specificitiesUp to 14 daysA sensitivity analysis estimating the range of sensitivities and specificities observed when imputing missing test device data
Sensitivity and Specificity in defined subgroupsUp to 14 daysSensitivity and Specificity in subgroups defined by: race, age-groups, activity level, skin-tone and AF-burden
Mean difference in Interbeat interval (IBI) and the associated limits of agreement (LoA)Up to 14 daysMean difference in Interbeat interval (IBI) and the associated limits of agreement (LoA) based on recorded ECG data
Participant-level and heartbeat level sensitivity/specificity of P-wave detectionUp to 14 daysParticipant-level and heartbeat level sensitivity/specificity of P-wave detection based on recorded ECG data

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026